Scinai Immunotherapeutics Ltd (NASDAQ:SCNI) — Market Cap & Net Worth
Market Cap & Net Worth: Scinai Immunotherapeutics Ltd (SCNI)
Scinai Immunotherapeutics Ltd (NASDAQ:SCNI) has a market capitalization of $1.27 Million ($1.27 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #30536 globally and #6209 in its home market, demonstrating a -10.59% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Scinai Immunotherapeutics Ltd's stock price $1.52 by its total outstanding shares 5169383 (5.17 Million). Also see SCNI total asset value for a full breakdown of the balance sheet.
Scinai Immunotherapeutics Ltd Market Cap History: 2015 to 2026
Scinai Immunotherapeutics Ltd's market capitalization history from 2015 to 2026. Data shows change from $2.05 Billion to $7.86 Million (-39.88% CAGR). Also see SCNI operating cash flow for how efficiently the company converts equity into cash flow.
Index Memberships
Scinai Immunotherapeutics Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.00% | #898 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #2854 of 3165 |
Weight: Scinai Immunotherapeutics Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Scinai Immunotherapeutics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Scinai Immunotherapeutics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Scinai Immunotherapeutics Ltd stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
2.81x
Scinai Immunotherapeutics Ltd's market cap is 2.81 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $17.29 Million | $658.00K | $4.80 Million | 26.28x | 3.61x |
| 2025 | $3.68 Million | $1.31 Million | -$8.31 Million | 2.81x | N/A |
Competitor Companies of SCNI by Market Capitalization
Companies near Scinai Immunotherapeutics Ltd in the global market cap rankings as of September 18, 2026. Review SCNI tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Scinai Immunotherapeutics Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Scinai Immunotherapeutics Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Scinai Immunotherapeutics Ltd's market cap moved from $2.05 Billion to $ 7.86 Million, with a yearly change of -39.88%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $7.86 Million | +113.45% |
| 2025 | $3.68 Million | -78.71% |
| 2024 | $17.29 Million | -43.78% |
| 2023 | $30.76 Million | -79.90% |
| 2022 | $153.01 Million | -87.40% |
| 2021 | $1.21 Billion | -16.37% |
| 2020 | $1.45 Billion | -69.75% |
| 2019 | $4.80 Billion | +94.76% |
| 2018 | $2.47 Billion | -11.01% |
| 2017 | $2.77 Billion | +60.00% |
| 2016 | $1.73 Billion | -15.40% |
| 2015 | $2.05 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Scinai Immunotherapeutics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.27 Million USD |
| MoneyControl | $1.27 Million USD |
| MarketWatch | $1.27 Million USD |
| marketcap.company | $1.27 Million USD |
| Reuters | $1.27 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Scinai Immunotherapeutics Ltd
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's s… Read more